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A major limitation in gene therapy for vectors derived from Moloney murine leukemia virus (MLV) is that they only deliver genes into
dividing cells. In this study, a careful comparison of spleen necrosis virus (SNV)-derived vectors with MLV and human immunodeficiency
virus (HIV)-1 retroviral vectors indicated that SNV vectors can deliver genes 4-fold more efficiently than MLV vectors into aphidicolin-
arrested cells, although at a 25-fold lower efficiency than HIV-1-derived vectors. Furthermore, the addition of a NLS in the SNV matrix (MA)
that mimics the one located in HIV-1 MA did not increase the ability of SNV vectors to transfer genes into arrested cells. Also, we found that
the RD114 envelope was able to pseudotype SNV viral particles in a very efficient manner.
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Gene transfer into hematopoietic stem cells has been
proposed for the treatment of inherited diseases that affect
blood cells (Klein and Baum, 2004). It is usually performed
in vitro using Moloney murine leukemia virus (MLV)-based
vectors, but it is necessary to stimulate cell division to allow
the transgene integration (Klein and Baum, 2004). Indeed,
in order for the preintegration complex (PIC) of the
retrovirus to enter the cell nucleus, the nuclear membrane
must be dissolved (Goff, 2001; Lewis and Emerman, 1994;
Miller et al., 1990; Roe et al., 1993). Then, the therapeutic
gene will integrate into the DNA of the cell, and it will be
transmitted to daughter cells (Goff, 2001). It has been
shown that the lentiviral vector is clearly superior to the
MLV vector for transduction of quiescent, primitive human
hematopoietic progenitor cells (Case et al., 1999; Miyoshi et
al., 1999; Sutton et al., 1998) and it seems that this property0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.05.024
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E-mail address: manuel.caruso@crhdq.ulaval.ca (M. Caruso).could be attributed to the active nuclear import of the human
immunodeficiency virus (HIV) PIC. The pathogenic nature
of HIV could limit its clinical use, and the production of the
lentiviral vector usually performed in transient transfection
renders the scale-up of the vector cumbersome (Reiser,
2000).
A vector derived from a retrovirus that is naturally
nonpathogenic to humans and that could efficiently trans-
port its PIC through the nuclear membrane would be ideal
for gene transfer into hematopoietic stem cells. Few years
ago, a vector derived from the gammaretrovirus spleen
necrosis virus (SNV) has been genetically engineered to
allow gene delivery into quiescent cells (Parveen et al.,
2000). A nuclear localization signal (NLS) was artificially
created in the matrix (MA) since it was believed that the
NLS located in the N-terminal region of HIV-1 MA was
critical for the entry of the virus PIC into the nucleus of
quiescent cells (Bukrinsky et al., 1993; Bukrinsky et al.,
1992; von Schwedler et al., 1994). SNV retroviral vectors
are not infectious to human cells (Gautier et al., 2000), and
therefore the pseudotyping with other envelopes (Env) is a05) 292 – 296
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could be a good candidate because the RD114 receptor is
highly expressed on human hematopoietic stem cells (Tailor
et al., 1999), and above all, it has been reported that MLV
and HIV vectors pseudotyped with RD114 Env can trans-
duce human CD34+ cells very efficiently (Kelly et al., 2000;
Sandrin et al., 2002).Results and discussion
First, the capacity of RD114 Env to pseudotype SNV
viral particles was investigated. SNV and RD114 Env show
approximately 50% identity at the amino acid level (Over-
baugh et al., 2001), and they belong to the same receptor
interference group (Koo et al., 1992). MLV and SNV
recombinant retroviruses containing the MLV RNA vector
GFP3 (Qiao et al., 2002) and displaying a vesicular
stomatitis virus G protein (VSV-G) or a RD114 Env at
their surface were produced in transient transfection. It has
been previously reported that SNV gag polyprotein pack-
ages efficiently MLV RNA (Certo et al., 1999; Embretson
and Temin, 1987) and that VSV-G Env is able to pseudotype
SNV viral particles (Dornburg, 2003). The pseudotyping
efficacy of SNV particles by RD114 Env was quantified by
measuring viral titers by GFP analysis. The titer measured
by FACS of SNV particles pseudotyped by RD114 Env was
1.9  104 GFP transducing unit (TU)/ml, and it was 2.5
times lower than the one found with VSV-G Env
pseudotyped SNV viruses. This difference in titer was
similar to the one found with MLV viral particles: 4.6  105
and 1.2  106 GFP TU/ml (Fig. 1). Therefore, we could
conclude that SNV viral particles can be pseudotyped in an
efficient manner by RD114 Env.Fig. 1. RD114 Env pseudotypes SNV viral particles. Titers are represented in GF
transfection and infection experiments. The abbreviations gp and e stand for gagThe next step was to create a NLS in SNV MA as
previously described by Parveen et al. (2000) in order to
produce viral particles that could transfer genes into
quiescent cells. The NLS in SNV MA was generated by
PCR-mediated site-directed mutagenesis; the alanine in
position 28 and the glycine in position 29 were,
respectively, changed for a tyrosine and a lysine. This
mutant shares 4 amino acids with the NLS of HIV-1 MA,
and it was shown to be the most efficient for generating
viral particles that could deliver genes into quiescent cells
(Parveen et al., 2000). Aphidicolin-arrested HT-1080 cells
were infected with SNV, SNV* (SNV with the NLS in
MA), HIV-1 or MLV retroviral particles pseudotyped with
VSV-G Env. Two days later, GFP fluorescent cells were
counted under a microscope to evaluate the viral titers. The
percentage of the number of infected aphidicolin-treated
HT-1080 cells (A) divided by the number of infected
dividing cells (D) was used to compare the vectors. A/D of
0.6% for MLV particles and 50.8% for HIV-1 particles
were found, and the values obtained were in the range of
those that have been reported by others (Hatziioannou and
Goff, 2001; Naldini et al., 1996; Trobridge and Russell,
2004). The A/D were 1.9% and 2.9% for SNV and SNV*
vectors, respectively (Fig. 2). Although the A/D values for
SNV vectors were higher than the one found for MLV,
these vectors were 25-fold less efficient than HIV-1-
derived vector to infect aphidicolin-arrested cells. More-
over, the addition of a NLS in SNV MA did not improve
the ability of SNV vector to deliver genes into quiescent
cells as previously reported (Parveen et al., 2000). We
obtained similar results with the D17 cell line that was
used by Parveen et al. to demonstrate that SNV*
recombinant viruses could infect efficiently quiescent cells
(data not shown).P transducing unit per ml, and they are the average T SD of 3 independent
-pol and Env, respectively.
Fig. 2. A nuclear localization signal inserted into SNV MA does not allow
the efficient retroviral infection of quiescent cells. A/D is the number of
infected aphidicolin-treated HT-1080 cells divided by the number of
infected dividing cells. The A/D ratios were calculated using the following
titers for quiescent and dividing cells, respectively: (a) MLV: 1.5  104 and
2.7  106 GFP TU/ml, (b) HIV-1: 6.6  106 and 1.3  107 GFP TU/ml, (c)
SNV: 1.1  103 and 5.9  104 GFP TU/ml and (d) SNV*: 1.5  103 and
5.1  104 GFP TU/ml. Viral titers were measured by counting GFP
fluorescent cells. The values are represented by the average T SD of an
experiment done 3 times.
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particles to transduce neuronal cells in vivo, but they could
not be certain that the neurons were quiescent at the time of
infection since the injections were made in newborn mice
(Parveen et al., 2003). The brain of these mice was still not
fully differentiated, and brain cells could still undergo some
cell division.
Many studies have strongly challenged the need of MA
NLS for the infection of nondividing cells by HIV-1
(Fouchier et al., 1997; Freed et al., 1995), and it has also
been shown that the entire globular domain of MA (which
contains the NLS) was dispensable for the infection of
nondividing cells (Reil et al., 1998). It has also been
demonstrated that the HIV-1 MA can efficiently replace the
MLV MA without affecting the virus infectivity. Never-
theless, the incorporation of the HIV-1 MA in MLV did not
allow the virus to replicate in growth-arrested cells
(Deminie and Emerman, 1994).
A NLS located in the HIV-1 integrase has also been
implicated in the nuclear entry of the PIC using the
importin/karyopherin pathway (Gallay et al., 1997), and a
NLS present in the integrase of Rous sarcoma virus is
suspected to be responsible for the property of this virus to
infect nondividing cells (Hatziioannou and Goff, 2001; Katz
et al., 2002). Different NLSs fused to the MLV integrase of a
replication-competent virus were also tested for their ability
to render MLV infection cell cycle-independent. Although
the viruses could replicate, they could not infect efficiently
quiescent cells (Seamon et al., 2002).
In conclusion, our data suggest that SNV viral particles
are more efficient than MLV vectors to infect aphidicolin-arrested cells, although they are 25-fold less efficient than
HIV-1-derived vectors. Also, our results indicate that the
addition of a NLS in SNV MA does not change the capacity
of SNV vectors to transduce quiescent cells as it was
reported by Parveen et al. (2000). Finally, we show in this
study that RD114 Env can pseudotype SNV particles
efficiently.Materials and methods
Plasmid construction
The SNV gag-pol plasmids were constructed as follows:
gag-pol was excised in SalI/PmeI from the SNV provirus
pPB101 (Bandyopadhyay and Temin, 1984) (ATCC, Man-
assas, VA) and was cloned under the control of the
cytomegalovirus immediate early enhancer/promoter region
(CMVi.e.) in the pCI plasmid (Promega, Madison, WI). A
version in which SNV gag-pol was under the control of the
elongation factor-1a promoter linked to the 5VRU5 untrans-
lated region of HTLV-1 (EF1a-RU5/HTLV) was also
constructed. The EF1a-RU5/HTLV sequence was isolated
from the plasmid pOrf-hCx43 (InvivoGen, San Diego, CA)
and was cloned instead of the CMVi.e. in the pCI plasmid.
The NLS in SNV MAwas generated by PCR-mediated site-
directed mutagenesis (the protocol will be available upon
request), and expression vectors with gag-pol SNV* were
also constructed similarly to the wild-type versions.
pVPack-Gag-Pol contained MLV gag-pol under the control
of a CMVi.e promoter, and it was commercially obtained
(Stratagene, La Jolla, CA). The RD114 Env expression
vector was also derived from pCI, and it was constructed as
follows: the 2.2-kb RD114 envelope gene from the proviral
clone Sc3c (a gift from Dr S. J. O_Brien) was digested by
ApaI/HincII followed by klenow treatment, and was cloned
in pCI digested by SmaI to give pCI-RD114Env. The
plasmid pMD2.G that encodes the VSV-G envelope, and the
lentiviral vector pHIV-GFP and the MLV vector GFP3 that
express EGFP have been described elsewhere (Dull et al.,
1998; He et al., 1997; Qiao et al., 2002).
Cell lines, transfection and infection
293T (human embryonic kidney), HT-1080 (human
fibrosarcoma, ATCC CCL-121) and D17 cells (dog osteo-
sarcoma, ATCC CRL-6248) were cultured with Dulbecco’s
modified Eagle_s medium (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal calf serum (Bio Cell,
Drumondville, Canada) and antibiotics. For the production
of recombinant viruses, subconfluent 293T cells were
transfected by the calcium phosphate procedure with 9.5
Ag of gag-pol plasmid (SNV or MLV derived), 12.5 Ag of
GFP3 vector and with 3 Ag of pMD2.G or pCI-RD114Env
plasmid in a 10-cm tissue culture dish. To produce the
lentiviral vector, 16.7 Ag of pHIV-GFP and 8.3 Ag of
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supernatant containing virus was harvested for titration. The
titer was determined as follows: HT-1080 cells were seeded
at 2  105 cells/well in a 6-well plate the day prior infection,
and the cells were infected with 1 ml of SNV supernatant or
100 Al of MLV supernatant in the presence of 8 Ag/ml
Polybrene (PB). The fluorescence of the cells was analyzed
with a flow cytometer (Beckam Coulter, Brea, CA, USA)
48 hours later, and the titer in GFP TU/ml was calculated
using the following formula (Sastry et al., 2002): titer =
(F  Co/V)  D. F is the frequency of GFP-positive cells
determined by flow cytometry; Co is the total number of
target cells infected; V is the volume of the inoculum; D is
the virus dilution factor.
Aphidicolin-arrested HT-1080 cells were used to assess
the capacity of SNV, SNV*, MLV and HIV-1 recombinant
viruses pseudotyped with VSV-G Env to infect quiescent
cells. Cells plated at 1.3  105 in 35-mm dish were
synchronized in serum-free medium overnight, and the next
morning, they were treated with aphidicolin (1 Ag/ml) at the
time of infection. Cells stained with propidium iodide at
different time points during the next 48 h showed a strong
block in G1/S as expected (data not shown). Arrested cells
were infected with 500 Al of SNV or SNV* virus, 50 Al of
MLV virus or 0.5 Al of HIV virus. Control untreated cells
that were dividing were infected with 50 Al of SNVor SNV*
virus, 5 Al of MLV virus or 0.5 Al of HIV virus. In this
experiment, the viral supernatant volumes were chosen
based on titers and the susceptibility of each virus to infect
quiescent cells. Forty-eight hours after infection, titers were
measured by counting the number of GFP-positive cells
under a fluorescent microscope in 10 independent fields.Acknowledgments
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